---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-052898"
form_type: "8-K"
ticker: "NUTX"
cik: "0001479681"
company_name: "Nutex Health Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:45:00.939800+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M

## Summary
- Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.
- Diluted EPS $9.69 vs diluted loss per share $10.39 in 2023; adjusted EBITDA $124.1M (up 1,046% YoY).
- Restatement adjustments: non-cash reclassifications increased liabilities $13.4M, decreased equity similarly; net income lowered ~$0.5M.
- Q4 2024 revenue $257.6M (+269.8% YoY); net income $61.6M vs net loss $31.6M in Q4 2023.
- Company notes stock repurchase program and arbitration process as ongoing; cash balance $40.6M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001628280-25-052898
- form_type: 8-K
- ticker: NUTX
- cik: 0001479681
- company_name: Nutex Health Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479681/000162828025052898/0001628280-25-052898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479681/000162828025052898/nutx-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-052898
- JSON: https://secwatch.observer/filing/0001628280-25-052898.json
- Plain text: https://secwatch.observer/filing/0001628280-25-052898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.